Most of the relevant data are within the paper and its Supporting Information files. Raw sequencing data has been uploaded to the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) (BioProject numbers: PRJNA608715, PRJNA608724).

Background {#sec005}
==========

Globally, tuberculosis (TB) remains one of the top ten causes of death \[[@pone.0232343.ref001]\]. TB treatment has been complicated by a rise in drug resistance, with treatment success rates of approximately 55% for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB (defined as resistance to both isoniazid (INH) and rifampicin (RIF)), and approximately 34% for extensively drug-resistant (XDR) TB (defined as MDR plus resistance to the fluoroquinolone (FQ) antibiotics and second-line injectable drugs) \[[@pone.0232343.ref001]\]. Commercially-available molecular assays, such as the GeneXpert^®^ MTB/RIF (Cepheid, Sunnyvale, CA) and the GenoType MDRTBplus (Bruker-Hain Diagnostics, Nehren, Germany), have shown excellent sensitivity and specificity for detecting RIF and RIF and INH resistance respectively. However, cost and technical complexity of these tests may be prohibitive in resource-limited areas. Additionally, these assays do not identify pyrazinamide (PZA) resistance, which is strongly associated with the success or failure of World Health Organization (WHO)-recommended shortening regimens \[[@pone.0232343.ref002]\].

Widespread use of TB drug susceptibility testing (DST) would aid in prevention and treatment of drug-resistant TB. Universal DST for at least RIF is recommended in all TB cases \[[@pone.0232343.ref003]\]. DST enables expanded use of standardized short course MDR treatments, which require susceptibility testing to major components of treatment before treatment initiation \[[@pone.0232343.ref002]\]. Broad use of culture or molecular-based DST methods has been difficult to achieve in resource-limited settings. Global surveillance data indicates that DST for RIF was only performed for 24% of new TB cases and 70% of previously treated cases in 2017 \[[@pone.0232343.ref001]\]. DST for PZA has been especially difficult to perform because phenotypic testing is technically challenging and nucleic acid amplification based tests (NAAT) must be able to identify hundreds of different mutations to effectively detect most cases of PZA resistance \[[@pone.0232343.ref004]\]. Performing DST at centralized locations might improve access to some types of drug susceptibility results, taking advantage of the economy of scale. However, safe, inexpensive, and efficient methods to collect, store, and transport sputum samples from TB patients to these centralized facilities present some challenges.

Much of the world obtains a TB diagnosis using microscopic examination of Acid Fast Bacilli (AFB) stained sputum smears. Microscopy is also widely used for disease monitoring, even in regions that have adopted molecular testing for initial TB diagnoses \[[@pone.0232343.ref003]\]. AFB smears on glass slides are easily stored and shipped; they do not require temperature controlled storage and are not infectious. A number of studies have shown that DNA can be extracted from AFB smears and then used in TB DST analysis using molecular and other DNA sequencing based methods \[[@pone.0232343.ref005]--[@pone.0232343.ref012]\]. However, most of these studies involved small sample sizes (\<100 slides) and only demonstrated the performance of their assays with one or two TB specific gene targets. Additionally, some studies used complex extraction and amplification protocols involving phenol-chloroform extractions, ethanol precipitations, and nested Polymerase Chain Reaction (PCR) amplifications requiring multiple primers for each target region, which would be impractical for widespread use.

We have developed a simple and effective method to extract *Mycobacterium tuberculosis* (MTB) DNA from clinically obtained AFB smears with sufficient quality for PCR amplification and next-generation DNA sequencing. We have also streamlined the process for PCR amplification of the isolated DNA for subsequent high-throughput sequencing of 17 regions of the *MTB* genome, enabling rapid detection of mutations associated with resistance to INH, RIF, ethambutol (EMB), PZA, FQ, and injectable aminoglycoside antibiotics. Here, we describe the method and assess the utility of our approach with 1,208 clinical AFB smears from Ghana, Kenya, Uganda, and Zambia. Since sequencing is becoming increasingly established as a definitive, reproducible, and reliable predictor of phenotypic DST, we also report the results of our new test desegregated by region and patient treatment status.

Methods {#sec006}
=======

AFB direct sputum microscopy smears {#sec007}
-----------------------------------

A convenience sample of clinically obtained direct AFB sputum smears (n = 2,227), collected between 2013 and 2016, was provided for evaluation with our assay. We utilized 635 of the slides to develop our assay. We processed an additional 1,208 smears (one per subject) with the final version of our assay, which is the focus of this manuscript. A summary of the study sample population and methods is presented in [Fig 1](#pone.0232343.g001){ref-type="fig"}. We excluded 384 smears from processing ([Fig 1](#pone.0232343.g001){ref-type="fig"}). We excluded scanty \[1 to 9 AFB in 100 fields\] smears because a preliminary evaluation of our assay showed suboptimal performance with such smears ([S1 Fig](#pone.0232343.s004){ref-type="supplementary-material"}). The slides included in this study consisted of 379 smears from the Ghanaian Armed Forces Health Care Beneficiary population seen at 37 Military Hospital, Accra, 517 smears from a PEPFAR population in the Western highlands of Kenya, 262 smears from the Uganda Peoples Defence Force and Ministry of Health hospitals and the Central Public Health Laboratory, Uganda, and 50 smears from Maina Soko Military Hospital serving the greater Lusaka area of Zambia.

![Flow diagram schematic of study sample population and methods.](pone.0232343.g001){#pone.0232343.g001}

In each country, smears were prepared based on standard protocols recommended for clinical use by their national TB control programs. Types of stains used included Kinyoun, Auramine-Rhodamine, and Ziehl--Neelsen. All smears were centrally graded at the Uniformed Services University of the Health Sciences (USUHS) based on the International Union Against Tuberculosis and Lung Disease (IUATLD) grading system \[[@pone.0232343.ref013]\]; this required stripping and re-staining the Auramine-Rhodamine stained slides with Kinyoun stain (Remel, Lenexa, KS, USA). In the remainder of this manuscript, wherever a reference is made to stain type, we are specifically referring to the original stain type used on the smear.

Ethics reviews {#sec008}
--------------

This study was reviewed and approved as non-human subjects research by the Institutional Review Boards (IRB) at the USUHS and Rutgers New Jersey Medical School, and it was reviewed and designated as an exempt protocol by the IRBs at the Naval Health Research Center, Walter Reed Army Institute of Research, Kenya Medical Research Institute, Makerere University, 37 Military Hospital, and the University of Zambia. Therefore, informed consent was waived by all aforementioned institutions. All data was anonymized before access by this study.

Smear extraction and DNA isolation {#sec009}
----------------------------------

Prior to extraction, the slides were washed with Xylene (Sigma Aldrich, Inc., Burlington, MA, USA) to remove immersion oil. For the extraction, 200 μl of Instagene Matrix (Bio-Rad Laboratories, Inc., Philadelphia, PA, USA) with 0.1% Triton X-100 (Sigma Aldrich, Inc., Burlington, MA, USA) was aliquoted into 1.5 mL Eppendorf tubes. Without disturbing the Chelex pellet, up to 100 μL of the Instagene Matrix and Triton X-100 solution was aspirated from the tube and dispensed onto the smear. The smear was then scraped off using a razor blade (Fisherbrand^™^ Razor Blades, Thermo Fisher Scientific, Inc., Hampton, NH, USA), aspirated off the slide, and transferred into the Eppendorf tube containing the Chelex pellet. To isolate the DNA, the extracted smear material was pulse vortexed at high speed for 30 seconds, then boiled for 20 minutes at 90°C, pulse vortexed on medium speed for 10 seconds, and centrifuged for 5 minutes at 15,000 rpm using Eppendorf Centrifuge 5424 (Eppendorf, Hamburg, Germany). The supernatant was transferred to a clean Eppendorf tube and purified using Qiagen QIAamp DNA Micro Kit (Qiagen, Inc., Germantown, MD, USA) according to manufacturer's instructions for cleanup of genomic DNA. The purified DNA was eluted in 45 μL of AE elution buffer from the kit.

Amplification targets and primers {#sec010}
---------------------------------

The drug resistance phenotypes, gene target regions, and the associated segment names and primers are shown in [Table 1](#pone.0232343.t001){ref-type="table"}. These target regions were selected to cover single nucleotide polymorphisms (SNPs) which have been reported to be associated with drug resistance in previous studies \[[@pone.0232343.ref014]--[@pone.0232343.ref016]\]. Mutation H57D in *pncA*, which occurs naturally in *M*. *bovis*, was excluded from downstream SNP analyses in this study. For *pncA*, the entire gene, including upstream and downstream flanking regions were targeted for amplification ([Table 1](#pone.0232343.t001){ref-type="table"}).

10.1371/journal.pone.0232343.t001

###### *Mycobacterium tuberculosis* gene regions targeted for detection of drug resistance associated mutations and associated primers.
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  Drug                                           Gene                         Segment Name      Targeted Nucleotide Positions        Primer Direction         Primer Sequence (5' to 3')
  ---------------------------------------------- ---------------------------- ----------------- ------------------------------------ ------------------------ ----------------------------
  Rifampicin                                     *rpoB*                       *rpoB*            1215 to 1383                         Forward                  `GATCACACCGCAGACGTTGA`
  Reverse                                        `ACGCTCACGTGACAGACCG`                                                                                        
  Isoniazid                                      *inhA promoter*              *inhA promoter*   nucleotide -160 to 44 of mabA gene   Forward                  `CCCAGAAAGGGATCCGTCAT`
  Reverse                                        `GATACGAATGGGGGTTTGGC`                                                                                       
  *katG*                                         *katG*                       809 to 992        Forward                              `CTGTTGTCCCATTTCGTCGG`   
  Reverse                                        `GGCGGTCACACTTTCGGTAA`                                                                                       
  Ethambutol                                     *embB*                       *emb10*           841 to 1017                          Forward                  `GCCGTGGTGATATTCGGCTT`
  Reverse                                        `CAGCGCCAGCAGGTTGTAAT`                                                                                       
  *emb20*                                        1156 to 1299                 Forward           `GCGGCGGCCATGGTCTTG`                                          
  Reverse                                        `CAGCGCCGCCGGTGTGA`                                                                                          
  *emb40*                                        1451 to 1550                 Forward           `CCGCCGGCACCGTCATCCTGA`                                       
  Reverse                                        `GCCTGGCTCGGCCCGATTTTG`                                                                                      
  Fluoroquinolones/ Moxifloxacin/ Ofloxacin      *gyrA*                       *gyrA*            159 to 395                           Forward                  `CCGGGTGCTCTATGCAATGT`
  Reverse                                        `GCTTCGGTGTACCTCATCGC`                                                                                       
  Fluoroquinolones                               *gyrB*                       *gyrB*            1390 to 1639                         Forward                  `GAGTTGGTGCGGCGTAAGAG`
  Reverse                                        `CCGTGATGATCGCCTGAACT`                                                                                       
  Kanamycin                                      *eis*                        *eis promoter*    -81 to 34                            Forward                  `CGTCCTCGGTCGGGCTACACAG`
  Reverse                                        `GCATCGCGTGATCCTTTGCCAGAC`                                                                                   
  Streptomycin                                   *rpsL*                       *rpsL0*           54 to 170                            Forward                  `GGTCAAGACCGCGGCTCTGA`
  Reverse                                        `AACTTCACGCGGGCAACCTTC`                                                                                      
  *rpsL1*                                        183 to +53                   Forward           `CGAGGTCACGGCGTACATTC`                                        
  Reverse                                        `GTAGACCGGGTCGTTGACCA`                                                                                       
  *rrs*                                          *rrs10*                      465 to 689        Forward                              `TCGGATTGACGGTAGGTGGA`   
  Reverse                                        `CATTCCACCGCTACACCAGG`                                                                                       
  Streptomycin /Amikacin/Capreomycin/Kanamycin   *rrs30*                      1368 to +59       Forward                              `ATACGTTCCCGGGCCTTGTA`   
  Reverse                                        `AGACAAGAACCCCTCACGGC`                                                                                       
  Pyrazinamide                                   *pncA*                       *pncA3*           -69 to 154                           Forward                  `CAACAGTTCATCCCGGTTCG`
  Reverse                                        `TCGGTATTGCCACCGATCAT`                                                                                       
  *pncA2*                                        111 to 337                   Forward           `CCAAGCCATTGCGTACCG`                                          
  Reverse                                        `ATCCCAGTCTGGACACGTCG`                                                                                       
  *pncA1*                                        245 to 454                   Forward           `CGTTCTCGTCGACTCCTTCG`                                        
  Reverse                                        `AGCGGCGGACTACCATCAC`                                                                                        
  *pncA0*                                        392 to +29                   Forward           `TGTGGAAGTCCTTGGTTGCC`                                        
  Reverse                                        `CCCTATATCTGTGGCTGCCG`                                                                                       

Polymerase Chain Reactions (PCR) {#sec011}
--------------------------------

All samples were amplified in 20 μL reactions. Smears graded 1+ were amplified in uniplex reactions containing 2 μl of target DNA to increase PCR efficacy and sequencing depth for these paucibacillary samples. For smears graded 2+ or 3+ all gene target sequences were amplified in duplexed reactions using 3 or 4 μL of target DNA per reaction, except for *gyrB*, which was only amplified in a uniplex reaction to maintain amplification efficiency. The PCR mix consisted of the following: 2.5 mM magnesium chloride (MgCl~2~)), 0.25 mM deoxyribonucleotides, 5% glycerol, 1X PCR buffer without MgCl~2~, 1 unit Jumpstart Taq DNA polymerase, and 0.5 μM primers (all reagents from Sigma Aldrich, Inc., Burlington, MA, USA). Samples were PCR-amplified in Roche LightCycler^®^ 480 System (Roche Molecular Systems, Inc., Branchburg, NJ, USA) and Applied Biosystems Prism 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, USA). For duplex reactions, primers were paired as follows: *rpoB-pncA3*, *rrs30-rpsL1*, *emb10-katG*, *emb20-eis*, *emb40-rpsL0*, *inhA-pncA2*, *gyrA-pncA0*, and *rrs10-pncA1*. All PCR products for each sample were pooled post amplification. For amplification, samples were denatured at 95°C for 1 minute followed by 40 cycles of touchdown PCR with the following parameters: 1) 10 cycles with 95°C denaturation for 15 seconds, annealing for 15 seconds starting at 70°C then lowered by 1°C with each subsequent cycle, and extension at 72°C for 30 seconds; 2) 30 cycles with 95°C denaturation for 15 seconds, annealing at 60°C for 15 seconds, and extension at 72°C for 30 seconds. With each PCR batch, a negative (dH~2~O) control, a wild type positive control (H37Rv genomic DNA), and genomic DNA extracted from a mutant positive control drug-resistant strain (TB-TDR-0114 or TB-TDR-0115)) were included \[[@pone.0232343.ref017]\]. These controls were also included in the downstream sequencing and SNP detection pipeline.

Sequencing {#sec012}
----------

The samples were sequenced at the HudsonAlpha GSL (Huntsville, AL, USA) using an Ilumina MiSeq^™^ platform (Illumina, Inc., San Diego, CA, USA) ([S1 Appendix](#pone.0232343.s001){ref-type="supplementary-material"}). Sequencing results have been deposited in the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) (BioProject numbers: PRJNA608715, PRJNA608724).

Data analysis {#sec013}
-------------

Reads were aligned to a reference sequence from the H37Rv strain of TB using an in-house bioinformatics pipeline ([S2 Appendix](#pone.0232343.s002){ref-type="supplementary-material"}). For each DST target region of a given slide, results were classified as interpretable if coverage depth of 20X or more reads was obtained; a mutation frequency of 80% or greater was considered sufficient for calling SNPs. If coverage depth of a DST target region was less than 20X, the results for that target region were classified as un-interpretable. Prevalence and corresponding exact binomial confidence intervals of mutations associated with resistance to first- and second-line anti-tuberculosis drugs were estimated for all slides with interpretable results for all gene targets.

Results {#sec014}
-------

Slide characteristics are summarized by country of origin in [Table 2](#pone.0232343.t002){ref-type="table"}. The 1,208 processed slides consisted of 282 (23.1%) 1+ smears, 352 (29.1%) 2+ smears, and 574 (47.5%) 3+ smears. All Kenya smears and 58% of Ghana smears were from adult patients. Information on adult or child status was missing for Uganda and Zambia smears. Over 61% of the smears were classified as new TB cases. The majority of the smears (42.8%) were from Kenya ([Table 2](#pone.0232343.t002){ref-type="table"}). Ziehl-Neelsen was the most frequently used stain ([Table 2](#pone.0232343.t002){ref-type="table"}).

10.1371/journal.pone.0232343.t002

###### Sample characteristics by country.
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  Sample Characteristics                                 Ghana (%)    Kenya (%)    Uganda (%)   Zambia (%)   Total (%)
  ------------------------------------------------------ ------------ ------------ ------------ ------------ ------------
  **Sample Size**                                        379 (31.4)   517 (42.8)   262 (21.7)   50 (4.1)     1208 (100)
  **Smear Grade**                                                                                            
  1+                                                     72 (19.0)    174 (33.7)   21 (8.0)     15 (30.0)    282 (23.3)
  2+                                                     62 (16.4)    141 (27.3)   131 (50.0)   18 (36.0)    352 (29.1)
  3+                                                     245 (64.6)   202 (39.1)   110 (42.0)   17 (34.0)    574 (47.5)
  **Stain Type**[^a^](#t002fn001){ref-type="table-fn"}                                                       
  Ziehl Neelsen                                          379 (100)    0            49 (18.7)    0            428 (35.4)
  Kinyoun                                                0            341 (66.0)   0            50 (100)     391 (32.4)
  Auramine/Rhodamine                                     0            176 (34.0)   207 (79.0)   0            383 (31.7)
  Unknown                                                0            0            6 (2.3)      0            6 (0.5)
  **Treatment Status**                                                                                       
  New case                                               172 (45.4)   352 (68.1)   221 (84.4)   0            745 (61.7)
  Follow Up                                              0            124 (24.0)   35 (13.4)    0            158 (13.1)
  Retreatment                                            0            38 (7.4)     4 (1.5)      0            43 (3.6)
  Unknown                                                207 (54.6)   3 (0.6)      2 (0.8)      50 (100)     262 (21.7)

^a^Stain type specified in this table is the original type of stain used on the smear at the clinical site where sample was collected.

Coverage depth varied by target region. The percentage of slides per smear grade with interpretable results overall and per target gene segments is reported in [Fig 2A](#pone.0232343.g002){ref-type="fig"}. With the exception of gyrB (interpretable results obtained in 79% of 1+ smears), interpretable results were obtained for any given target gene segment in 80% or more of slides, regardless of smear grade ([Fig 2A](#pone.0232343.g002){ref-type="fig"}). Interpretable results was obtained for all targets in 194 (68.8%) 1+ smears, 246 (69.9%) 2+ smears, 430 (74.9%) 3+ smears, and 870 (72%) slides overall. The number of mapped reads varied by target gene segment and slide smear grade, ranging from approximately 300X for *rrs10* to over 12000X for the *eis* promoter on average. Median coverage per target region, stratified by smear grade, is shown in [Fig 2B](#pone.0232343.g002){ref-type="fig"}. Coverage depth also varied by stain type. Interpretable results were obtained for all targeted gene segments in over 94% of Kinyoun stained smears, but only 64% of Ziehl-Neelsen stained smears, and 59% of Auramine/Rhodamine stained smears ([S1 Table](#pone.0232343.s005){ref-type="supplementary-material"}).

![Percent of samples per smear grade with interpretable results and median number of mapped reads per target gene segment.\
A) Percent of samples per smear grade with interpretable results (coverage depth of 20X or greater) for all and specified target gene segments; B) Sequence coverage in median number of mapped reads per target gene segment, stratified by smear grade.](pone.0232343.g002){#pone.0232343.g002}

A summary of all drug resistance associated mutations detected in all gene targets are presented in [Table 3](#pone.0232343.t003){ref-type="table"}. RIF resistance associated mutations in *rpoB* were detected in 6.3% of new cases, 3.3% of follow-up cases (patients under initial treatment), 20.0% of retreatment cases ([S2 Table](#pone.0232343.s006){ref-type="supplementary-material"}), and 6.1% of slides overall ([Table 3](#pone.0232343.t003){ref-type="table"}). The highest rate of RIF resistance associated mutations were detected in slides from Uganda (18.3%), followed by slides from Zambia (8.51%). Over 85% of RIF resistance associated mutations occurred in codon 445 (alternative numbering system: 526) of *rpoB* ([Table 3](#pone.0232343.t003){ref-type="table"}).

10.1371/journal.pone.0232343.t003

###### Summary of drug resistance associated mutations detected in direct AFB smears and total number of drug resistant smears from Ghana, Kenya, Uganda, and Zambia, by drug type[^a^](#t003fn001){ref-type="table-fn"}.
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  Drug                                                     Gene Segment               Nucleotide (Reference/Mutant)   Amino Acid Alteration[^b^](#t003fn002){ref-type="table-fn"}   Ghana               Kenya               Uganda                                                       Zambia             Total
  -------------------------------------------------------- -------------------------- ------------------------------- ------------------------------------------------------------- ------------------- ------------------- ------------------------------------------------------------ ------------------ --------------------------------------------------------------
  Rifampicin                                               *rpoB*                     1289 CTG/ CCG                   L430P (L511P)                                                 0/345               0/496               2/246                                                        0/47               2/1134
  1295 CAA/ CCA                                            Q432P (Q513P)              1/345                           0/496                                                         0/246               0/47                1/1134                                                                          
  1304 GAC/ GTC                                            D435V (D516V)              0/345                           1/496                                                         0/246               1/47                2/1134                                                                          
  1333 CAC/GAC                                             H445D (H526D)              1/345                           0/496                                                         41/246              3/47                45/1134                                                                         
  1333 CAC/TAC                                             H445Y (H526Y)              2/345                           10/496                                                        0/246               0/47                12/1134                                                                         
  1333 CAC/AAC                                             H445N (H526N)              1/345                           0/496                                                         0/246               0/47                1/1134                                                                          
  1349 TCG/ TTG                                            S450L (S531L)              2/345                           0/496                                                         2/246               0/47                4/1134                                                                          
  1355 CTG/ CCG                                            L452P (L533P)              2/345                           0/496                                                         0/246               0/47                2/1134                                                                          
  **Total Rifampicin Resistant Smears (%)**                                                                                                                                         **9/345 (2.61)**    **11/496 (2.22)**   **45/246 (18.29)**                                           **4/47 (8.51)**    **69/1134 (6.08)**
  Isoniazid                                                *inhA Promoter*            -15 C/T                         Promoter                                                      3/326               0/476               2/166                                                        0/47               5/1015
  *katG*                                                   944 AGC/ACC                S315T                           24/337                                                        14/501              16/218              6/47                                                         60/1103            
  **Total Isoniazid Resistant Smears (%)**                                                                                                                                          **27/316 (8.54)**   **14/473 (2.96)**   **18/168 (10.71)**                                           **6/47 (12.77)**   **65/1004 (6.47)**
  Streptomycin                                             *rpsL0*                    128 AAG/AGG                     K43R                                                          14/365              13/512              0/242                                                        0/50               27/1169
  *rpsL1*                                                  263 AAG/AGG                K88R                            5/312                                                         0/490               3/204               0/47                                                         8/1053             
  *rrs10*                                                  513 A/C                                                    0/319                                                         3/480               0/186               0/48                                                         3/1033             
  *rrs10*                                                  516 C/T                                                    0/319                                                         0/480               2/186               0/48                                                         2/1033             
  **Total Streptomycin Resistant Smears (%)**                                                                                                                                       **19/292 (6.51)**   **16/468 (3.42)**   **5/179 (2.79)**                                             **0/47**           **40/986 (4.06)**
  Ethambutol                                               *embB10*                   916 ATG/GTG                     M306V                                                         2/343               13/500              4/218                                                        1/47               20/1108
  *embB10*                                                 918 ATG/ATA                M306I                           1/343                                                         0/500               2/218               0/47                                                         3/1108             
  *embB20*                                                 1190 GGC/GAC               G406D                           0/360                                                         0/505               3/228               1/47                                                         4/1140             
  **Total Ethambutol Resistant Smears (%)**                                                                                                                                         **3/339 (0.88)**    **13/496 (2.62)**   **7/218 (3.21)**[^**c**^](#t003fn003){ref-type="table-fn"}   **2/47 (4.26)**    **25/1100 (2.27)**[^**c**^](#t003fn003){ref-type="table-fn"}
  Fluoroquinolones                                         *gyrA*                     281 GAC/GGC                     D94G                                                          2/314               12/486              0/200                                                        0/47               14/1047
  **Total Fluoroquinolones Resistant Smears (%)**^**g**^                                                                                                                            **2/281 (0.71)**    **12/459 (2.61)**   **0/180**                                                    **0/46**           **14/966 (1.45)**
  Moxifloxacin/ Ofloxacin                                  *gyrA*                     281 GAC/GGC                     D94G                                                          2/314               12/486              0/200                                                        0/47               14/1047
  **Total Moxifloxacin/ Ofloxacin Resistant Smears (%)**                                                                                                                            **2/314 (0.64)**    **12/486 (2.47)**   **0/200**                                                    **0/47**           **14/1047 (1.34)**
  Pyrazinamide                                             *pncA3*                    -11 A/G                         Promoter                                                      0/319               10/475              0/170                                                        0/46               10/1010
  *pncA3*                                                  11 TTG/TCG                 L4S                             0/319                                                         1/475               0/170               0/46                                                         1/1010             
  *pncA3*                                                  35 GAC/GCC                 D12A                            0/319                                                         0/475               1/170               0/46                                                         1/1010             
  *pncA3*                                                  37 TTC/CTC                 F13L                            1/319                                                         0/475               0/170               0/46                                                         1/1010             
  *pncA3*                                                  104 CTG/CGG                L35R                            0/319                                                         0/475               0/170               2/46                                                         2/1010             
  *pncA3*                                                  137 GCA/GTA                A46V                            1/319                                                         0/475               0/170               0/46                                                         1/1010             
  *pncA2*                                                  151 CAC/TAC                H51Y                            1/327                                                         0/487               0/199               0/47                                                         1/1060             
  *pncA2*                                                  185 CCG/CAG; 185 CCG/CTG   P62Q; P62L Mixture              1/327                                                         0/487               0/199               0/47                                                         1/1060             
  *pncA2*                                                  188 GAC/GGC                D63G                            0/327                                                         0/487               2/199               0/47                                                         2/1060             
  *pncA2*                                                  202 TGG/CGG                W68R                            1/327                                                         0/487               0/199               0/47                                                         1/1060             
  *pncA1*                                                  322 GGA/AGA                G108R                           1/335                                                         0/496               0/211               0/48                                                         1/1090             
  **Total Pyrazinamide Resistant Smears (%)**                                                                                                                                       **6/302 (1.99)**    **11/467 (2.36)**   **3/160 (1.88)**                                             **2/46 (4.35)**    **22/975 (2.26)**

^a^ A coverage depth cut-off of 20X and a frequency cut-off of 80% was used for all reported single nucleotide polymorphisms. For each target gene segment, the number of smears with SNPs out of the total number of smears with 20X or greater coverage for the given target gene segment are reported per country. For each country and in total, the percent of smears with resistance to a given drug were calculated by dividing the number of smears with at least one mutation associated with resistance to the given drug by the total number of smears in which all relevant target gene segments (listed in [Table 1](#pone.0232343.t001){ref-type="table"}) were successfully screened plus any smears in which at least one associated target gene segment met the coverage cut-off and contained a drug resistance associated mutation.

^b^ For rpoB0, the amino acid number is presented in the MTB numbering system followed by the alternative numbering system in parentheses.

^c^ Two samples from Uganda contained a drug resistant associated mutation in both *emb10* and *emb20* gene segments. The numerator has been adjusted to ensure we do not double count these samples in calculating percent of etambutol resistant smears from Uganda and overall.

INH resistance associated mutations in *katG* and/or *inhA* were detected in 6% of slides overall, with the highest rate being among Zambia slides (12.8%), followed by Uganda (10.7%) ([Table 3](#pone.0232343.t003){ref-type="table"}). Most (92%) of the observed INH resistance associated mutations were S315T in *katG* ([Table 3](#pone.0232343.t003){ref-type="table"}). Overall, fluoroquinolones, moxifloxacin, and ofloxacin resistance associated mutations in *gyrA* were observed in over 1% of slides ([Table 3](#pone.0232343.t003){ref-type="table"}). PZA resistance associated mutations in *pncA* were observed in over 2% of slides overall ([Table 3](#pone.0232343.t003){ref-type="table"}). Majority of the distinct *pncA* mutations were only detected in a single slide. However, the -11 A/G mutation in the *pncA* promoter was observed in 2.4% of Kenya slides. Detected *pncA* SNPs for which there currently is little to no evidence of an association with drug resistance are reported in [S3 Table](#pone.0232343.s007){ref-type="supplementary-material"}. We did not detect any SNPs in our wild-type positive controls or negative controls.

Prevalence estimates and associated 95% confidence intervals for detected drug resistance mutation profiles in smears with interpretable results for all DST gene targets, stratified by country are presented in [Table 4](#pone.0232343.t004){ref-type="table"}. Overall, drug resistance associated SNPs were detected in 88/870 (Estimate: 10.11%; 95% CI: 8.19%, 12.31%) of the slides with interpretable results for all DST gene targets, with mutation rates being highest in slides from Zambia ([Table 4](#pone.0232343.t004){ref-type="table"}). Approximately 58% of the slides in which a drug resistance associated mutation was detected contained a SNP associated with mono-resistance to RIF, INH, or SM, with the most frequent mutation being associated with INH resistance ([Table 4](#pone.0232343.t004){ref-type="table"}). A MDR mutation profile with resistance to at least RIF and INH was also observed in 8% (95% CI: 2.48%, 21.22%) of smears from Zambia and in 1.8% (95% CI: 1.05%, 2.97%) of smears overall ([Table 4](#pone.0232343.t004){ref-type="table"}). No XDR mutation profiles were identified.

10.1371/journal.pone.0232343.t004

###### Prevalence and 95% confidence intervals for detected drug resistance mutation profiles in smears with interpretable results for all target gene segments, stratified by country[^a^](#t004fn001){ref-type="table-fn"}.
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  Mutation Based Drug Resistance Profile                     Ghana                Kenya              Uganda              Zambia           Total                                                                                            
  ---------------------------------------------------------- -------------------- ------------------ ------------------- ---------------- -------------------- ----------------- ------------------ ----------------- -------------------- -----------------
  **Mono-resistance**                                                                                                                                                                                                                      
  RIF only                                                   1/264 (0.38)         0.01, 2.09         10/434 (2.30)       1.11, 4.20       6/127 (4.72)         1.75, 10.00       0/45 (0.00)        0.00, 7.87        17/870 (1.95)        1.14, 3.11
  INH only                                                   14/264 (5.30)        2.93, 8.74         0/434               0.00, 0.85       6/127 (4.72)         1.75, 10.00       2/45 (4.44)        0.54, 15.15       22/870 (2.53)        1.59, 3.80
  SM only                                                    9/264 (3.41)         1.57, 6.37         2/434 (0.46)        0.06, 1.66       0/127 (0.00)         0.00, 2.86        0/45 (0.00)        0.00, 7.87        11/870 (1.26)        0.63, 2.25
  PZA only                                                   0/264 (0.00)         0.00, 1.39         0/434 (0.00)        0.00, 0.85       0/127 (0.00)         0.00, 2.86        1/45 (2.22)        0.06, 11.77       1/870 (0.11)         0.00, 0.64
  **Multi-drug Resistance**                                                                                                                                                                                                                
  RIF and INH                                                4/264 (1.52)         0.41, 3.83         0/434 (0.00)        0.00, 0.85       1/127 (0.79)         0.02, 4.31        3/45 (6.67)        1.40, 18.27       8/870 (0.92)         0.40, 1.80
  RIF, INH, and one or more of the following: EMB, SM, PZA   3/264 (1.14)         0.23, 3.28         1/434 (0.23)        0.01, 1.28       3/127 (2.36)         0.49, 6.75        1/45 (2.22)        0.06, 11.77       8/870 (0.92)         0.40, 1.80
  **Poly-resistance**                                                                                                                                                                                                                      
  Two or more of the following: INH, SM, EMB, PZA            6/264 (2.27)         0.84, 4.88         0/434 (0.00)        0.00, 0.85       3/127 (2.36)         0.49, 6.75        1/45 (2.22)        0.06, 11.77       10/870 (1.15)        0.55, 2.10
  FQ, MXF, and OFL                                           1/264 (0.38)         0.01, 2.09         0/434 (0.00)        0.00, 0.85       0/127 (0.00)         0.00, 2.86        0/45 (0.00)        0.00, 7.87        1/870 (0.11)         0.00, 0.64
  INH, EMB, SM, PZA, FQ, MXF, OFL                            0/264 (0.00)         0.00, 1.39         10/434 (2.30)       1.11, 4.20       0/127 (0.00)         0.00, 2.86        0/45 (0.00)        0.00, 7.87        10/870 (1.15)        0.55, 2.10
  **Total**                                                  **38/264 (14.39)**   **10.39, 19.22**   **23/434 (5.30)**   **3.99, 7.85**   **19/127 (14.96)**   **9.25, 22.37**   **8/45 (17.78)**   **8.00, 32.05**   **88/870 (10.11)**   **8.19, 12.31**

^a^Abbreviations: RIF = rifampicin; INH = isoniazid; SM = streptomycin; PZA = pyrazinamide; EMB = ethambutol; FQ = fluoroquinolone; MXF = moxifloxacin; OFL = ofloxacin; CI = confidence interval.

Presented in [Table 5](#pone.0232343.t005){ref-type="table"} are overall and country specific prevalence estimates and 95% confidence intervals for phenotypic interpretation of observed mutations in smears with interpretable results for all DST gene targets, stratified by case treatment status. Among smears with interpretable results for all gene targets, 7.8% of new cases, 4.1% of follow up cases, and 28.1% of retreatment cases had mutation profiles for mono-resistance, MDR, or poly-resistance.

10.1371/journal.pone.0232343.t005

###### Overall and country specific prevalence and 95% confidence intervals for phenotypic interpretation of observed mutations in smears with interpretable results for all gene targets, by case treatment status.
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  Case Treatment Status by Country   No Drug Resistance    Mono-Resistance    Multi-Drug Resistance   Poly-Resistance   Any Drug Resistant Smears                                                                              
  ---------------------------------- --------------------- ------------------ ----------------------- ----------------- --------------------------- ---------------- ------------------- ---------------- -------------------- -----------------
  **Ghana**                                                                                                                                                                                                                    
  New                                111/125 (88.80)       81.92, 93.74       13/125 (10.40)          5.65, 17.13       1/125 (0.80)                0.02, 4.38       0/125 (0.00)        0.00, 2.91       14/125 (11.20)       6.26, 18.08
  Unknown                            115/139 (82.73)       75.41, 85.61       11/139 (7.91)           4.02, 13.72       6/139 (4.32)                1.60, 9.16       7/139 (5.04)        2.05, 10.10      24/139 (17.27)       11.39, 24.59
  **Total**                          226/264 (85.61)       80.78, 89.61       24/264 (9.09)           5.91, 13.22       7/264 (2.65)                1.07, 5.39       7/264 (2.65)        1.07, 5.39       38/264 (14.39)       10.39, 19.22
  **Kenya**                                                                                                                                                                                                                    
  New                                287/297 (96.63)       93.90, 98.37       4/297 (1.35)            0.37, 3.41        1/297(0.34)                 0.01, 1.86       5/297 (1.68)        0.55, 3.88       10/297 (3.37)        1.63, 6.10
  Follow-up                          100/104 (96.15)       90.44, 98.94       1/104 (0.96)            0.02, 5.10        0/104 (0.00)                0.00, 3.48       3/104 (2.88)        0.60, 8.20       4/104 (3.85)         1.06, 9.56
  Retreatment                        23/31 (74.19)         55.39, 88.14       7/31 (22.58)            9.59, 41.10       0/31 (0.00)                 0.00, 11.22      1/31 (3.23)         0.08, 16.70      8/31 (25.81)         11.86, 44.61
  Unknown                            1/2 (50.00)           1.26, 98.74        0/2 (0.00)              0.00, 84.19       0/2 (0.00)                  0.00, 84.19      1/2 (50.00)         1.26, 98.74      1/2 (50.00)          1.26, 98.74
  **Total**                          411/434 (94.70)       92.15, 96.61       12/434 (2.76)           1.44, 4.78        1/434 (0.23)                0.01, 1.28       10/434 (2.30)       1.11, 4.20       23/434 (5.30)        3.39, 7.85
  **Uganda**                                                                                                                                                                                                                   
  New                                90/107 (84.11)        75.78, 90.46       12/107 (11.21)          5.93, 18.77       3/107 (2.80)                0.58, 7.98       2/107 (1.87)        0.23, 6.59       17/107 (15.89)       9.54, 24.22
  Follow-up                          17/18 (94.44)         72.71, 99.86       0/18 (0.00)             0.00, 18.53       1/18 (5.56)                 0.14, 27.29      0/18 (0.00)         0.00, 18.53      1/18 (5.56)          0.14, 27.29
  Retreatment                        0/1 (0.00)            0.00, 97.50        0/1 (0.00)              0.00, 97.50       0/1(0.00)                   0.00, 97.50      1/1 (100.00)        2.50, 100.00     1/1 (100.00)         2.50, 100.00
  Unknown                            1/1 (100)             2.50, 100.00       0/1 (0.00)              0.00, 97.50       0/1(0.00)                   0.00, 97.50      0/1 (0.00)          0.00, 97.50      0/1(0.00)            0.00, 97.50
  **Total**                          108/127 (85.04)       77.63, 90.75       12/127 (9.45)           4.98, 15.92       4/127 (3.15)                0.86, 7.87       3/127 (2.36)        0.49, 6.75       19/127 (14.96)       9.25, 22.37
  **Zambia**                                                                                                                                                                                                                   
  Unknown                            37/45 (82.22)         67.95, 92.00       3/45 (6.67)             1.40, 18.27       4/45 (8.89)                 2.48, 21.22      1/45 (2.22)         0.06, 11.77      8/45 (17.78)         8.00, 32.05
  **Total**                          37/45 (82.22)         67.95, 92.00       3/45 (6.67)             1.40, 18.27       4/45 (8.89)                 2.48, 21.22      1/45 (2.22)         0.06, 11.77      8/45 (17.78)         8.00, 32.05
  **Overall**                                                                                                                                                                                                                  
  New                                488/529 (92.25)       89.63, 94.38       29/529 (5.48)           3.70, 7.78        5/529 (0.95)                0.31, 2.19       7/529 (1.32)        0.53, 2.71       41/529 (7.75)        5.62, 10.37
  Follow-up                          117/122 (95.90)       90.69, 98.66       1/122 (0.82)            0.02, 4.48        1/122 (0.82)                0.02, 4.48       3/122 (2.46)        0.51, 7.02       5/122 (4.10)         1.34, 9.31
  Retreatment                        23/32 (71.88)         53.25, 86.25       7/32 (21.88)            9.28, 39.97       0/32 (0.00)                 0.00, 10.89      2/32 (6.25)         0.77, 20.81      9/32 (28.13)         13.75, 46.75
  Unknown                            153/187 (81.82)       75.53, 87.07       14/187 (7.49)           4.15, 12.24       10/187 (5.35)               2.59, 9.61       9/187 (4.81)        2.22, 8.94       33/187 (17.65)       12.47, 23.88
  **Total**                          **782/870 (89.89)**   **87.69, 91.81**   **51/870 (5.86)**       **4.40, 7.64**    **16/870 (1.84)**           **1.05, 2.97**   **21/870 (2.41)**   **1.50, 3.67**   **88/870 (10.11)**   **8.19, 12.31**

We re-sequenced a subset of the slides using Sanger sequencing to confirm the accuracy of our MiSeq based approach. This included 16 slides with a wild type *pncA* gene, 61 with *rpoB* mutations, 18 with *KatG* mutations, and 27 additional slides with mutations in other gene targets. Our Sanger sequencing results matched the results of our primary study in every case except for one slide where an H445D mutation was detected in *rpoB* by MiSeq (coverage depth: 1700X; mutation frequency: 99%) but not Sanger sequencing ([S1](#pone.0232343.s008){ref-type="supplementary-material"}, [S2](#pone.0232343.s009){ref-type="supplementary-material"} and [S3](#pone.0232343.s010){ref-type="supplementary-material"} Data).

Discussion {#sec015}
==========

We have demonstrated that DNA of sufficient quality for PCR amplification and next generation DNA sequencing can be isolated from AFB stained direct sputum smears and tested for mutations associated with resistance to all first and several second line anti-tuberculosis drugs. The DNA isolation method we have developed is simple and rapid and does not require much technical expertise. The samples used in this study were comprised of a diverse set of clinically obtained smears in terms of smear grade, AFB stain type, and geographic origin. Although the percentage of slides that met the coverage cut-off of 20X was similar for all target gene segments, the median number of reads for each target varied. This indicates that while sufficient DNA can be isolated from 1+ to 3+ smears to amplify and sequence all gene segments tested in this study, certain targets (e.g., *eis* promoter) are amplified more efficiently than others by the selected primer pairs. Kinyoun stained smears enabled better sequencing coverage compared to other stain types. However, the poor performance with Auramine/Rhodamine stained smears could in part be due to subsequent stripping and counterstaining of these slides with Kinyoun stain at USUHS, which may have resulted in DNA loss. Given that each country mainly used one type of stain, the variation observed in coverage depth by stain type could also be due to site-specific factors ([Table 2](#pone.0232343.t002){ref-type="table"}).

Our assay demonstrated well-established associations of drug-resistance with geographical region and TB treatment status. Although the number of retreatment cases in our study was small, the rate of RIF resistance associated mutations we observed in retreatment cases as compared to new cases was similar to trends currently reported for the continent of Africa, where the rate of drug resistance mutations in retreatment cases is almost four times that observed in new TB cases \[[@pone.0232343.ref003]\]. The countries from which slides were analyzed in our study are on the WHO's list of top high burden countries for TB (Kenya; Zambia), MDR-TB (Kenya), and/or TB-HIV concurrent infections (Zambia; Ghana; Uganda) \[[@pone.0232343.ref003]\]. Comprehensive genotypic drug resistance surveillance data for these countries is currently limited. Based on national surveillance data, less than 2% of new TB cases are drug-resistant in all countries from which slides were included in our study \[[@pone.0232343.ref003]\]. Although our sample size for each country was small and subject treatment status was only known for a subset of our samples, the estimated prevalence of drug resistance among new TB cases in our study was over ten times higher than reported national rates for Ghana and Uganda. Among Kenyan smears in our sample, the estimated drug resistance rate was almost three times higher than the reported national rate. It could be that a greater number of drug-resistant cases were evaluated at the facilities that we received our samples from because they are centralized laboratories. The drug resistance rate estimated among Zambian smears in our sample was similar to the national rate of 18% reported for relapse cases in Zambia \[[@pone.0232343.ref003]\]. However, the subject treatment status associated with the Zambian slides in our study was unknown. Similar to findings from previous phenotypic and molecular drug resistance surveillance studies \[[@pone.0232343.ref018]--[@pone.0232343.ref026]\], we found INH mono-resistance associated mutations to be more common in samples overall than RIF mono-resistance or RIF-INH dual resistance. Noted is that Ghana likely has both *M*. *africanum* and *M*. *tuberculosis* infection in clinically identified TB subjects, cited as up to 40% in West Africa \[[@pone.0232343.ref024]\]. This may be relevant to our study, as *M*. *africanum* has been reported to have less drug resistance compared to *M*. *tuberculosis* in Ghana \[[@pone.0232343.ref025]\]. Differentiation between *M*. *africanum* and *M*. *tuberculosis* was not possible with the target regions we sequenced.

A limitation of this study is that our specimens were obtained from central or regional reference laboratories and thus may not be generalizable to the entire population. Another limitation is that the observed drug resistance mutations could not be confirmed via phenotypic DST, given that the study was conducted retrospectively. Nevertheless, we were able to validate the in-house bioinformatics pipeline that was used to analyze our samples by reanalyzing the data for 384 slides with the previously published ASAP pipeline \[[@pone.0232343.ref026]\]. We observed no discordance between the variant calls made by our pipeline and the ASAP pipeline when adjusting coverage cut-off to 20X and SNP frequency to 80% ([S3 Appendix](#pone.0232343.s003){ref-type="supplementary-material"}). Also, limiting our screening process only to previously published drug-resistant mutations may have led to an underestimation of drug resistance in our samples.

Among the slides processed by Sanger and MiSeq sequencing, one discordant sample was observed, where *rpoB* mutation H445D (alternate naming system: H526D) was detected by MiSeq but not by Sanger sequencing. Given the length of the *rpoB* target, coverage of codon 445 was only available from the forward direction from Sanger sequencing. It is possible that the *rpoB* SNP was missed by Sanger sequencing in this sample. Alternatively, the portion of the discordant sample amplified by MiSeq sequencing may have been contaminated. Regardless, the overall concordance between the two approaches was very high. Although precautions were taken to prevent contamination, some samples could have been contaminated during sample processing.

Our approach has several potential advantages compared to phenotypic DSTs and to currently available rapid molecular DST tests. Our approach is free from the biohazards associated with phenotypic DST and can be performed without use of expensive biocontainment laboratories. Compared to commercially available rapid molecular tests, our use of targeted DNA sequencing enables easy expansion to detect additional resistance mutations as well as mutations to new drugs as needed. The total reagent costs for our approach, including all assay steps, was approximately \$50 per slide, for slides amplified with duplex PCR, and \$60 for slides amplified with uniplex PCR. However, with additional multiplexing of the PCR step and with expected decreases in next generation sequencing costs, it is likely that our approach could soon become less expensive than other DST methods. Aside from the smear scraping step, slides can be batch processed at every step of the process. Slide scraping to DNA purification can be completed for at least 12 samples in less than an hour.

In summary, we have demonstrated a simple and rapid method for determining drug resistance in a widely available sample type, AFB stained sputum microscopy smears, which is easily storable, and safely transportable without infectious risk. This approach should prove useful for diagnosing drug-resistant TB as well as for surveillance purposes.

Future research may add mycobacterial speciation targets, which may determine the frequency of positive acid-fast microscopy caused by mycobacteria other than MTB.
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